Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18919082 | COMPOSITIONS FOR TREATING CANCER | October 2024 | June 2025 | Allow | 8 | 1 | 1 | No | No |
| 18897951 | BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF | September 2024 | June 2025 | Allow | 8 | 1 | 0 | No | No |
| 18660672 | ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF | May 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18656081 | ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 17993654 | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies | November 2022 | June 2025 | Abandon | 31 | 3 | 0 | Yes | No |
| 16972895 | SET OF REAGENTS FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS | November 2021 | June 2025 | Abandon | 54 | 1 | 0 | No | No |
| 17434286 | THERAPEUTIC ANTIGEN BINDING PROTEINS SPECIFIC FOR CD93 AND METHODS OF USE THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 0 | No | No |
| 17428650 | METHODS AND COMPOSITIONS FOR TREATING CANCER | August 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17380445 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17380483 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17422186 | ANTI-B7S1 POLYPEPTIDES AND THEIR USE | July 2021 | March 2025 | Allow | 45 | 1 | 0 | No | No |
| 17421770 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17420537 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | July 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17418906 | PATHOGEN BINDING PROTEINS | June 2021 | June 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17415993 | CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT | June 2021 | May 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17350995 | ANTIBODIES SPECIFIC TO MUC18 | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17306913 | 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis | May 2021 | December 2024 | Allow | 43 | 3 | 1 | No | No |
| 17287164 | METHODS AND MATERIALS FOR TREATING CANCER | April 2021 | November 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17267115 | ANTI-IL-1beta ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME | February 2021 | February 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17258245 | CO-RECEPTOR SYSTEMS FOR TREATING INFECTIOUS DISEASES | January 2021 | December 2024 | Allow | 48 | 2 | 1 | No | No |
| 17251397 | METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS | December 2020 | October 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17048748 | T CELL RECEPTORS WITH MAGE-B2 SPECIFICITY AND USES THEREOF | October 2020 | September 2024 | Allow | 47 | 1 | 1 | No | No |
| 16999823 | METHODS FOR SCAR PREVENTION | August 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16969056 | CD83-BINDING CHIMERIC ANTIGEN RECEPTORS | August 2020 | June 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16651531 | METHOD FOR DEPLETING CYTOTOXIC T CELLS USING AN ANTI-LAG-3 ANTIBODY COMPOSITION | March 2020 | July 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16291207 | Treatment of Type 1 Diabetes and Other Conditions Using the Gut Microbiome | March 2019 | September 2021 | Abandon | 31 | 2 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner GUSTILO, ESTELLA M works in Art Unit 1646 and has examined 22 patent applications in our dataset. With an allowance rate of 54.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner GUSTILO, ESTELLA M's allowance rate of 54.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GUSTILO, ESTELLA M receive 1.64 office actions before reaching final disposition. This places the examiner in the 44% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GUSTILO, ESTELLA M is 46 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +45.7% benefit to allowance rate for applications examined by GUSTILO, ESTELLA M. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 12.5% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.0% of cases where such amendments are filed. This entry rate is in the 16% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.